Can I pause immunotherapy if my cancer is stable and ctDNA negative?
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial is testing whether people with advanced solid tumors who have responded well to immunotherapy and have no detectable cancer DNA in their blood can safely pause treatment. If eligible, you would be randomly assigned to either continue your current immunotherapy or stop it under close monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic cancer (melanoma, NSCLC, MSI-high colorectal cancer, kidney cancer, or another solid tumor that has spread).
- You have been receiving immunotherapy (e.g., a PD-1 inhibitor alone or with a CTLA-4 inhibitor) for at least 6 months (for melanoma or MSI-high CRC) or 12 months (for other cancers) and up to 15 months.
- Your most recent scan shows your tumor has shrunk or disappeared (complete or partial response) within the last 6 weeks.
- You have had at least 2 blood tests (6 weeks apart) showing no detectable cancer DNA (ctDNA), with the most recent test within the last month.
- You are generally well enough to carry out daily activities (ECOG score 0-2) and have adequate organ function (kidney, liver, blood counts).
- You do not have active brain metastases, an autoimmune disease needing treatment in the past 2 years, or a history of severe lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
This trial is testing a simple blood test to see if it can predict how well immunotherapy will work for people with advanced cancer. It's for those newly diagnosed with certain cancers and about to start immunotherapy as their first treatment.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This Phase 2 study tests how results from blood cancer DNA tests (ctDNA) can help choose the best immune therapy approach for newly diagnosed, advanced lung cancer. It aims to improve outcomes by matching treatment decisions to a patient’s immune and blood test “profile.”
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
This trial studies whether it’s safe to stop nivolumab (an immunotherapy) after your melanoma has responded well to initial treatment with ipilimumab plus nivolumab. It may help some people avoid ongoing treatment side effects while still keeping the cancer controlled.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.